Insmed (NASDAQ:INSM) COO Sells $140,406.14 in Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 802 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14. Following the transaction, the chief operating officer directly owned 109,660 shares of the company’s stock, valued at approximately $19,198,176.20. This represents a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Price Performance

Shares of Insmed stock traded down $5.73 during trading on Thursday, hitting $170.27. The stock had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The firm has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. The business’s 50-day moving average is $190.79 and its 200 day moving average is $151.24.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.27) EPS. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. ORG Partners LLC grew its position in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank purchased a new position in Insmed in the 2nd quarter worth approximately $28,000. Stone House Investment Management LLC bought a new stake in Insmed in the third quarter valued at approximately $29,000. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INSM. HC Wainwright decreased their price objective on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Guggenheim decreased their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. UBS Group lowered their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research report on Tuesday. Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Bank of America increased their target price on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.